MYRIAD GENETICS INC — Director's Dealing 2021

Sep 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MYRIAD GENETICS INC (MYGN)
CIK: 0000899923
Period of Report: 2021-09-21

Reporting Person: Verratti Mark (President, Myriad Neuroscience)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-21	Common Stock	A	10000	$0.0	Acquired	166048	Direct
2021-09-21	Common Stock	A	46571	$0.0	Acquired	212619	Direct

Footnotes

F1: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date.

F2: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.